30, Jun 2026
ActiveMind Daily Invites Families Across India to Become Founding Families Pilot for Adults over 50
Bengaluru, June 30: ActiveMind Daily, a doctor-led movement for brain wellness through prevention and good ageing, invites families across India to be a part of its Founding Families Pilot. This is an early access scheme mainly for adults aged 50 years and over.
The pilot is designed to inspire modest, meaningful everyday activities to support memory, contemplation, creativity, discussion and cognitive engagement. This program has been produced by a group of doctors. The programme’s main aim is to foster lifelong brain-healthy practices among older persons. This means habits like creating family relationships through everyday contact.
The Founding Families Pilot allows participants to experience ActiveMind Daily before it is available to the general public. Participants are invited to contribute valuable feedback to help shape and develop the programming.
Pilot participants will receive:
-
Complimentary participation in the Founding Families Pilot
-
Early access before the public launch
-
A special gift from the ActiveMind Daily team
-
Dedicated support throughout the pilot
-
An opportunity to help shape the programme through participant feedback
-
Recognition as a Founding Family
The pilot is accessible for families with a parent, grandparent or loved one 50 years of age or older. Participation is limited, and the ActiveMind Daily staff will contact the selected applicants individually after registration.
How to Participate:
Families wishing to sign up for the Founding Families Pilot may visit the following:
https://activeminddaily.in/#
- 0
- By Neel Achary
30, Jun 2026
Simplify Genomics and SimonMed Announce Collaboration to Advance Preventive Healthcare Through Integrated Genomics and Imaging
Combining whole genome interpretation with large-scale whole-body MRI to enable a more comprehensive view of human health
San Diego, CA — June 30, 2026 — Simplify Genomics today announced a collaboration with SimonMed aimed at advancing a more integrated approach to preventive healthcare. By combining SimonMed’s national scale in whole-body MRI with Simplify’s Whole Genome Interpretation and Reporting Platform, the collaboration seeks to provide a more complete picture of human health— helping identify risk earlier, personalize care pathways, and support more proactive health decisions. Across both imaging and genomics, there is growing evidence that early indicators associated with disease may be identified well before they surface in traditional care pathways. Together, these modalities offer complementary perspectives: genomics can provide insight into underlying disease risk, while imaging can help identify existing structural or physiological changes.
Simplify Genomics has spent years developing and refining its clinical reporting platform as a CAP/CLIA-certified laboratory and has processed in excess of 50,000 whole genomes to date. The platform includes thousands of disease associations and a broad set of pharmacogenomic insights, designed to support clinical interpretation and integration within real-world care settings.
Paired with SimonMed’s leadership in accessible, AI-enhanced imaging at national scale—including a network of more than 175 imaging centers across the United States —the collaboration creates an opportunity to explore patterns and connections that may not be visible through any single modality alone, supporting earlier insight and helping to inform clinical decision-making.
“This collaboration reflects a shared vision for the future of healthcare—one that is more proactive, data-driven, and personalized,” said Travis Lacey, CEO of Simplify Genomics.
“We believe the future of healthcare lies in making advanced preventive insights more accessible and actionable,” said John Simon, CEO of SimonMed. “By combining imaging and genomics, we have an opportunity to help patients and providers better understand health risk earlier and with greater clarity.” The collaboration is progressing rapidly, with additional updates expected in the near future.
29, Jun 2026
JP Nadda launches WhatsApp-based Ayushman Sarathi chatbot, unified drug registry
June 29: Union Health Minister J.P. Nadda has launched the Ayushman Sarathi WhatsApp chatbot along with a Unified Drug Registry to make healthcare services more accessible and digitally connected.
The WhatsApp chatbot will help citizens easily access information about government health schemes, hospital services, eligibility, and other health-related queries in a simple and quick way.
The Unified Drug Registry will act as a central digital system to track medicines and improve their availability, monitoring, and regulation across the healthcare system.
Officials said the initiative aims to make healthcare services more transparent, efficient, and citizen-friendly by using widely accessible digital platforms.
29, Jun 2026
Govt invites proposals to cut import dependence in medical devices
June 29: The government has invited proposals from industry, startups, academic institutions, research organisations, and innovators to reduce India’s dependence on imported medical devices and strengthen the country’s domestic manufacturing ecosystem.
The initiative aims to identify practical solutions that can accelerate indigenous production, promote innovation, and address critical technology gaps in the medical devices sector. It seeks to encourage the development of high-quality, affordable medical equipment that can meet India’s growing healthcare needs while reducing reliance on overseas suppliers.
Officials said the proposals will help shape policies and support mechanisms to strengthen research and development, encourage investment in advanced manufacturing, and foster collaboration between industry, academia, and government. The move is also expected to improve supply chain resilience, enhance India’s competitiveness in the global medical devices market, and create new opportunities for startups and manufacturers.
The initiative forms part of the government’s broader vision of building a self-reliant healthcare ecosystem under the Atmanirbhar Bharat initiative, ensuring reliable access to critical medical technologies while positioning India as a global hub for medical device innovation and manufacturing.
29, Jun 2026
KIMS Hospitals Creates Global History as the World’s First Healthcare Network to Achieve AACI Multi-Site Accreditation
Hyderabad, June 29: KIMS Hospitals has achieved a historic global milestone by becoming the world’s first healthcare network to receive the AACI Multi-Site Accreditation from the American Accreditation Commission International . This landmark recognition establishes a new global benchmark for integrated healthcare quality, patient safety, governance, and clinical excellence across a multi-hospital healthcare network.
The accreditation recognizes seven KIMS Hospitals operating under a unified quality management and governance framework, demonstrating that internationally benchmarked standards can be consistently implemented and sustained across multiple hospitals.
Unlike conventional accreditation programs that assess individual hospitals independently, the AACI Multi-Site Accreditation evaluates an entire healthcare network as one integrated system. The assessment focuses on leadership, governance, patient safety, clinical excellence, standardized care delivery, risk management, and continuous quality improvement across all participating hospitals.
By successfully meeting these rigorous international standards, KIMS Hospitals has become the first healthcare network in the world to receive this prestigious recognition, reaffirming its commitment to delivering a consistent patient experience and world-class healthcare across every accredited facility.
“This is a proud moment for every member of the KIMS family. Becoming the world’s first healthcare network to achieve AACI Multi-Site Accreditation reflects the culture of quality, teamwork, and patient-first care that we have built over the years. This recognition inspires us to raise the bar even higher.”
Dr. B. Bhaskar Rao, Chairman & Managing Director, KIMS Group of Hospitals, said
“Three years ago, one of our hospitals received AACI accreditation. This achievement was the result of the collective efforts of our clinicians, nurses, quality professionals, administrators, and leadership team. Building on that success, we have now implemented the same quality framework across six more hospitals. Through standardized clinical protocols, robust governance systems, evidence-based practices, and a strong culture of continuous quality improvement, KIMS Hospitals has demonstrated that excellence in healthcare can be delivered consistently across an entire hospital network.”
KIMS Group of Hospitals Director Anita said that this recognition is the result of the collective efforts of the doctors, nurses, quality teams, administrative staff, and leadership across the seven KIMS hospitals. She particularly appreciated the outstanding contribution of Ms. Sushma Katuri, General Manager – Group Quality, KIMS Group, for her pivotal role in achieving this milestone. She further stated that KIMS has demonstrated its ability to successfully implement uniform standards across its entire hospital network through standardized clinical protocols, robust quality systems, efficient governance, and a culture of continuous improvement.
Congratulating KIMS Hospitals on this historic achievement, Kreso Antonio Paliska, Group CEO of AACI, highlighted the significance of this milestone for healthcare organizations worldwide.
“KIMS Hospitals has set a new global benchmark. Achieving the world’s first AACI Multi-Site Accreditation demonstrates what is possible when leadership, quality, and patient safety become part of an organization’s everyday culture. We are proud to recognize KIMS for this historic achievement.”
Kreso Antonio Paliska Group CEO, American Accreditation Commission International Speaking on the achievement, Dheeraj Khatore, Regional CEO – AACI India, Middle East & Africa, emphasized the broader impact of the recognition.
“This is more than an accreditation—it’s a milestone for global healthcare. KIMS Hospitals has shown that world-class quality can be delivered consistently across seven hospitals under one integrated quality framework. We are proud to partner with KIMS in setting this new international benchmark.”
Dheeraj Khatore Regional CEO – AACI India, Middle East & Africa This historic achievement not only reinforces KIMS Hospitals’ leadership in healthcare quality but also establishes a scalable model for integrated healthcare systems around the world. As healthcare networks continue to expand globally, the ability to maintain consistent standards across multiple facilities has become increasingly important. KIMS Hospitals has demonstrated that quality, patient safety, and clinical excellence can be standardized across an entire healthcare system without compromising patient-centered care.
The AACI Multi-Site Accreditation reflects KIMS Hospitals’ unwavering commitment to innovation, accountability, operational excellence, and continuous quality improvement. More importantly, it assures patients that every accredited KIMS Hospital operates under the same internationally benchmarked standards, ensuring a consistent, safe, and high-quality healthcare experience.
29, Jun 2026
New laboratory tool opens door to better treatments for rare and deadly melanomas
| Researchers have created a powerful new cellular model to study rare tumours that are resistant to immunotherapies. The tool could change how therapies are developed for aggressive melanomas that currently have almost no effective treatment options. |
|
A research team at the University of Turku in Finland have developed a reliable laboratory model to study BAP1-deficient melanomas, which are a rare type of melanoma that evade the immune system once they have metastasized and are universally resistant to current state-of-the-art immunotherapies. Metastatic BAP1-deficient melanoma is the most common intraocular malignancy in adults, but it remains rare and extremely difficult to treat once it spreads. When the disease reaches the liver, as it does in roughly half of patients, median survival is measured in months. Unlike common melanomas, BAP1-deficient melanomas do not respond to the immune checkpoint therapies that have transformed cancer care over the past decade. The key driver behind the tumour’s immune evasion is the loss of a gene called BAP1 (BRCA1-associated protein 1). When BAP1 is lost, tumours become more aggressive, grow faster, and suppress the immune cells that would otherwise attack them. BAP1 loss is the most important molecular event in uveal melanoma progression, and it also plays a role in mesothelioma, renal cell carcinoma, and other cancers. However, scientists have been unable to study the consequences of BAP1 loss properly in the laboratory, because no suitable immune-competent model existed. Gene editing solved the missing puzzle pieceTo address the issue, the research team used CRISPR-Cas9 gene editing to delete BAP1 from normal melanocyte cells, creating a new pre-clinical tumour model that behaves like human BAP1-deficient melanoma in an animal with a fully functioning immune system. “BAP1 loss is associated with poor prognosis and resistance to immunotherapy in melanoma. Until now, there has been no preclinical model that faithfully reproduces the tumour–immune interactions seen in patients. Our model fills this gap, for the first time, by recapitulating the human tumour immune microenvironment in vivo. This provides a powerful platform to study how BAP1 loss drives immune evasion and to test novel immunotherapy combinations that may overcome treatment resistance,” explains lead researcher of the study, Dr Mona Wang Meng from the University of Turku. The absence of a proper laboratory model has been one of the biggest bottlenecks slowing down drug development for BAP1-deficient melanoma and related rare tumours. Previous models either lacked a functional immune system, making them useless for immunotherapy studies, or carry too many confounding mutations that obscure the specific role of BAP1. “The implications go well beyond melanoma. BAP1 loss is a shared vulnerability across several hard-to-treat cancers. This platform allows us, and research groups worldwide, to rationally design and test new immunotherapy combinations — something that simply was not possible before,” says Dr Carlos R. Figueiredo, the Principal Investigator of the study. The study was published in the journal Communications Biology. It is part of the broader research programme of MIORG within the InFLAMES Research Flagship at the University of Turku, which focuses on harnessing the immune system to fight cancer.
|
27, Jun 2026
Centre to launch Aarogya Setu 2.0 to boost digital healthcare access
New Delhi, June 2026: The Government of India is set to launch Aarogya Setu 2.0, along with a series of new digital health initiatives aimed at strengthening inclusive and accessible healthcare across the country.
The upgraded platform will focus on providing citizens with enhanced health tracking, real-time medical alerts, telemedicine support, and improved integration with government health services. Officials said the new version will be more user-friendly, secure, and connected with India’s expanding digital health ecosystem.
Alongside Aarogya Setu 2.0, the government is also rolling out additional digital initiatives designed to improve health data management, early disease detection, and access to healthcare services in rural and underserved areas.
Health authorities stated that these initiatives are part of a broader mission to build a digitally empowered and inclusive healthcare system, ensuring better reach, faster response, and improved public health outcomes.
The launch is expected to significantly strengthen India’s digital health infrastructure and support the goal of universal healthcare access.
27, Jun 2026
CM Vijay to Launch Statewide Pulse Polio Campaign in Tamil Nadu
Chennai, June 27: Chief Minister Vijay will launch a statewide Pulse Polio Immunization Campaign in Tamil Nadu on Sunday, reinforcing the government’s commitment to sustaining polio-free status and strengthening child health initiatives across the state.
The campaign aims to ensure 100% immunization coverage for children under the age of five through widespread vaccination drives at hospitals, primary health centres, schools, and designated booths across all districts.
State health officials have made extensive preparations, including setting up immunization booths, mobilizing healthcare workers, and coordinating with local administration to ensure smooth implementation of the drive. Awareness campaigns have also been intensified to encourage maximum participation from parents and guardians.
The Pulse Polio initiative remains a critical public health program, focusing on preventing the re-emergence of poliovirus and maintaining high levels of community immunity. The state government continues to prioritize child health and preventive healthcare through regular immunization efforts.
The Chief Minister’s participation in the launch event underscores the administration’s focus on strengthening public health infrastructure and ensuring the well-being of children across Tamil Nadu.
26, Jun 2026
How Artificial Intelligence is Quietly Transforming Healthcare for Better, Faster, and Safer Care
Artificial Intelligence (AI) is no longer a future concept in healthcare—it is already reshaping how diseases are detected, how treatments are planned, and how hospitals operate every day. From early diagnosis to personalised medicine, AI is helping doctors work faster, reduce errors, and deliver more focused patient care.
What makes this shift important is not just technology, but the way it improves real human lives—by catching illnesses earlier, reducing delays, and making healthcare more accessible and efficient.
1. Earlier, Smarter Detection of Diseases
One of AI’s biggest strengths lies in its ability to detect patterns that are often invisible to the human eye. By analysing scans such as X-rays, MRIs, and CT images, AI systems can identify early signs of diseases like cancer, heart disorders, and neurological conditions.
This early insight allows doctors to begin treatment sooner, often improving recovery chances and reducing complications. In many cases, AI acts as a second set of eyes—supporting doctors in making more confident decisions.
2. Care Designed Around Each Patient
Healthcare is becoming more personalised thanks to AI. Instead of a “one-size-fits-all” approach, AI uses patient history, genetic data, and lifestyle information to help doctors design more targeted treatments.
This means fewer side effects, better outcomes, and treatments that are more closely aligned with each patient’s unique health condition. It is a shift toward truly individualised care.
3. Preventing Illness Before It Becomes Serious
AI is helping healthcare move from treatment to prevention. By studying patterns in health records and real-time data, AI can identify early warning signs of chronic illnesses such as diabetes, hypertension, and heart disease.
This allows doctors to intervene early—before conditions become severe—reducing hospital visits and improving long-term health outcomes.
4. Making Hospitals Run More Smoothly
Behind the scenes, AI is helping hospitals become more efficient. Tasks like appointment scheduling, billing, record management, and insurance processing are increasingly being automated.
This reduces pressure on healthcare staff and gives doctors more time to focus on patients rather than paperwork. It also helps reduce delays and improves overall hospital organisation.
5. Faster Development of New Medicines
Developing new drugs traditionally takes years, but AI is speeding up this process. It can analyse large sets of chemical and biological data to identify promising drug candidates more quickly.
This is especially important for complex diseases, where faster research can lead to life-saving treatments reaching patients sooner.
6. Continuous Health Monitoring Outside Hospitals
With wearable devices and smart sensors, patients can now be monitored even at home. AI continuously tracks vital signs like heart rate, oxygen levels, and blood sugar.
If something unusual is detected, alerts are sent to healthcare providers immediately. This is especially helpful for patients with chronic conditions who need constant monitoring.
7. Virtual Health Support Anytime
AI-powered virtual assistants are making healthcare more accessible. They help patients with reminders, basic health questions, appointment scheduling, and guidance.
This 24/7 support system ensures that patients are never completely disconnected from healthcare assistance, even outside hospital hours.
8. Helping Doctors Make Better Decisions
AI acts as a support system for doctors by analysing patient data and comparing it with global medical research. It provides evidence-based suggestions that help in diagnosis and treatment planning.
This is especially useful in complex cases where multiple treatment options exist.
9. Improving Patient Experience
AI is also making healthcare more patient-friendly. Faster processing, reduced waiting times, and better communication tools improve the overall experience for patients.
With fewer administrative burdens, healthcare providers can spend more meaningful time with patients, improving trust and care quality.
10. Smarter Hospital Management
Hospitals use AI to predict patient inflow, manage staff schedules, and allocate resources more efficiently. This helps avoid overcrowding and ensures better service during peak demand periods.
It also improves planning and reduces stress on healthcare systems.
Conclusion
Artificial Intelligence is not replacing doctors—it is supporting them. It is helping healthcare systems become faster, more accurate, and more human-focused.
By combining technology with medical expertise, AI is shaping a future where healthcare is not only more advanced but also more personal, preventive, and accessible to all.
26, Jun 2026
India Reviews Residual Shelf-Life Norms for Imported Pharmaceuticals
New Delhi, June 26: The government has invited comments and suggestions from stakeholders on the proposed framework concerning residual shelf-life requirements for imported pharmaceutical products, as part of ongoing efforts to strengthen regulatory clarity and ensure the availability of quality medicines in the country.
The consultation exercise aims to review and rationalise existing provisions governing the minimum residual shelf-life required for drugs at the time of import clearance. The objective is to ensure a balanced approach that safeguards patient safety while also improving ease of doing business for the pharmaceutical sector.
Officials said the proposed review seeks to align regulatory requirements with current global practices and supply chain realities, particularly in cases where medicines are imported to meet urgent clinical or public health needs. The initiative is also expected to reduce procedural bottlenecks and improve the efficiency of drug availability in the domestic market.
Stakeholders, including pharmaceutical manufacturers, importers, industry associations, healthcare professionals, and other concerned parties, have been requested to submit their comments and feedback within the stipulated timeframe.
The government will examine all suggestions received during the consultation process before finalising the revised guidelines on residual shelf-life requirements for imported drugs. The updated framework is expected to enhance regulatory transparency while ensuring uninterrupted access to essential medicines.
